Home › Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection
 

Keywords :   


Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection

2013-07-16 18:01:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, confirmed today that the U.S. Food and Drug Administration (FDA) has cancelled Thursdays discussion of sugammadex at the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). Sugammadex sodium injection is Mercks investigational medicine for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium. Language:  English Contact:  MerckMedia:Pam Eisele, 908-423-5042Sarra Herzog, 908-423-6154orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: statement meeting committee advisory

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
04.10Should you tip even if the service wasn't worth it?
04.10Hurricane Kirk Graphics
04.10Hurricane Kirk Forecast Discussion Number 22
04.10Tropical Storm Leslie Forecast Discussion Number 10
04.10Hurricane Kirk Wind Speed Probabilities Number 22
04.10Hurricane Kirk Public Advisory Number 22
04.10Summary for Hurricane Kirk (AT2/AL122024)
04.10Tropical Storm Leslie Public Advisory Number 10
More »